CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net income (loss)	$ 101,027	$ 267,303	$ 334,757
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of real estate, in-place lease, and other intangibles	1,058,865	1,057,205	749,901
Stock-based compensation amortization expense	14,410	15,543	14,480
Merger-related post-combination stock compensation expense	0	16,223	0
Amortization of deferred financing costs and debt discounts (premiums)	31,907	28,974	11,916
Straight-line rents	(39,190)	(41,276)	(14,387)
Amortization of above (below) market lease intangibles	(36,747)	(30,755)	(25,791)
Amortization of non-refundable entrance fees	(98,912)	(88,995)	(83,197)
Equity loss (income) from unconsolidated joint ventures	173,984	1,515	(10,204)
Distributions of earnings from unconsolidated joint ventures	17,117	12,000	910
Deferred income tax expense (benefit)	3,845	(1,693)	(14,605)
Impairments and loan loss reserves (recoveries), net	(893)	22,978	(5,601)
Loss (gain) on sales of real estate, net	(69,488)	(178,695)	(86,463)
Loss (gain) upon change of control, net	0	(77,548)	(234)
Casualty-related loss (recoveries), net	621	29,076	(3,085)
Other non-cash items	(10,332)	(6,133)	4,900
Changes in:
Decrease (increase) in accounts receivable and other assets	(16,267)	(40,860)	(21,566)
Increase (decrease) in accounts payable, accrued liabilities, and other liabilities	(25,285)	(28,640)	(40,732)
Increase (decrease) in deferred revenue	147,297	114,275	145,243
Net cash provided by (used in) operating activities	1,251,959	1,070,497	956,242
Cash flows from investing activities:
Acquisitions of real estate	(486,703)	(6,787)	(15,847)
Development, redevelopment, and other major improvements of real estate	(763,656)	(597,494)	(731,206)
Leasing costs, tenant improvements, and recurring capital expenditures	(133,951)	(115,784)	(113,596)
Proceeds from sales of real estate, net	337,724	648,548	141,651
Proceeds from the Callan Ridge JV transaction, net	0	125,662	0
Investments in unconsolidated joint ventures	(86,773)	(61,602)	(88,391)
Distributions in excess of earnings from unconsolidated joint ventures	28,503	22,906	20,640
Proceeds from insurance recovery	20,043	8,711	24,980
Proceeds from sales/principal repayments on loans receivable and other	148,295	93,445	204,865
Investments in loans receivable and other	(98,155)	(52,189)	(19,850)
Cash paid in connection with the Merger, net	0	(179,215)	0
Net cash provided by (used in) investing activities	(1,034,673)	(113,799)	(576,754)
Cash flows from financing activities:
Borrowings under bank line of credit and commercial paper	12,121,070	3,741,250	10,344,705
Repayments under bank line of credit and commercial paper	(11,192,220)	(4,311,250)	(10,620,311)
Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt	987,260	750,000	743,778
Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt	(807,432)	(26,780)	(90,089)
Payments for deferred financing costs	(2,730)	(19,784)	(7,322)
Issuance of common stock, net of offering costs	1,146	317	278
Repurchase of common stock	(97,145)	(190,690)	(6,524)
Dividends paid on common stock	(849,095)	(794,783)	(657,021)
Distributions to and purchase of noncontrolling interests	(37,867)	(89,708)	(45,282)
Contributions from and issuance of noncontrolling interests	13,124	12	489
Net cash provided by (used in) financing activities	136,111	(941,416)	(337,299)
Net increase (decrease) in cash, cash equivalents, and restricted cash	353,397	15,282	42,189
Cash, cash equivalents, and restricted cash, beginning of year	184,305	169,023	126,834
Cash, cash equivalents, and restricted cash, end of year	$ 537,702	$ 184,305	$ 169,023